Aquina Christopher T, Eskander Mariam F, Pawlik Timothy M
Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Digestive Health and Surgery Institute, AdventHealth Orlando, Orlando, FL, United States.
Front Oncol. 2022 Jan 31;12:832405. doi: 10.3389/fonc.2022.832405. eCollection 2022.
Recurrence following curative-intent hepatectomy for colorectal cancer liver metastasis, hepatocellular carcinoma, or cholangiocarcinoma is unfortunately common with a reported incidence as high as 75%. Various treatment modalities can improve survival following disease recurrence. A review of the literature was performed using PubMed. In addition to systemic therapy, liver-directed treatment options for recurrent liver disease include repeat hepatectomy, salvage liver transplantation, radiofrequency or microwave ablation, intra-arterial therapy, and stereotactic body radiation therapy. Repeat resection can be consider for patients with limited recurrent disease that meets resection criteria, as this therapeutic approach can provide a survival benefit and is potentially curative in a subset of patients. Salvage liver transplantation for recurrent hepatocellular carcinoma is another option, which has been associated with a 5-year survival of 50%. Salvage transplantation may be an option in particular for patients who are not candidates for resection due to underlying liver dysfunction but meet criteria for transplantation. Ablation is another modality to treat patients who recur with smaller tumors and are not surgical candidates due to comorbidity, liver dysfunction, or tumor location. For patients with inoperable disease, transarterial chemoembolization, or radioembolization with Yttrium-90 are liver-directed intra-arterial therapy modalities with relatively low risks that can be utilized. Stereotactic body radiation therapy is another palliative treatment option that can provide a response and local tumor control for smaller tumors.
不幸的是,对于结直肠癌肝转移、肝细胞癌或胆管癌进行根治性肝切除术后复发很常见,据报道发生率高达75%。疾病复发后,各种治疗方式均可改善生存率。我们使用PubMed对文献进行了综述。除全身治疗外,针对复发性肝病的肝脏定向治疗选择包括再次肝切除、挽救性肝移植、射频或微波消融、动脉内治疗以及立体定向体部放射治疗。对于复发性疾病局限且符合切除标准的患者可考虑再次切除,因为这种治疗方法可带来生存获益,并且在一部分患者中可能具有治愈性。复发性肝细胞癌的挽救性肝移植是另一种选择,其5年生存率为50%。挽救性移植可能特别适用于因潜在肝功能障碍而不适合切除但符合移植标准的患者。消融是治疗肿瘤较小且因合并症、肝功能障碍或肿瘤位置而不适合手术的复发患者的另一种方式。对于无法手术的患者,经动脉化疗栓塞或钇-90放射性栓塞是可采用的风险相对较低的肝脏定向动脉内治疗方式。立体定向体部放射治疗是另一种姑息性治疗选择,可为较小肿瘤提供缓解和局部肿瘤控制。